The PK/PD study showed that the β1-adrenergic inhibitory effect plateaus at the lower dose tested in the Phase2b study (400 mg/day). The higher dose (600 mg/day) is more efficacious in terms of chorea control while bearing a limited risk for cardiovascular safety similar to that of the lower doses.